Fexuprazan

A medication used for the treatment of acid-related disorders

Fexuprazan
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Fexuprazan is a medication used primarily for the treatment of gastroesophageal reflux disease (GERD) and other acid-related disorders. It belongs to a class of drugs known as potassium-competitive acid blockers (P-CABs), which work by inhibiting the action of the proton pump in the stomach lining, thereby reducing the production of gastric acid.

Mechanism of Action

Fexuprazan functions by selectively and reversibly inhibiting the H+/K+ ATPase enzyme system, commonly referred to as the proton pump, in the gastric parietal cells. Unlike proton pump inhibitors (PPIs), which require activation in an acidic environment, P-CABs like fexuprazan can inhibit acid secretion more rapidly and consistently, providing a more immediate therapeutic effect.

Pharmacokinetics

Fexuprazan is absorbed in the gastrointestinal tract and reaches peak plasma concentrations within a few hours of administration. It has a relatively long half-life, allowing for once-daily dosing. The drug is metabolized primarily in the liver and excreted through the kidneys.

Clinical Uses

Fexuprazan is indicated for the treatment of:

• Gastroesophageal reflux disease (GERD)
• Peptic ulcer disease
• Zollinger-Ellison syndrome

Side Effects

Common side effects of fexuprazan include headache, diarrhea, nausea, and abdominal pain. As with other acid-reducing medications, long-term use may be associated with an increased risk of gastrointestinal infections and nutrient malabsorption, such as vitamin B12 deficiency.

Comparison with Other Acid-Reducing Agents

Fexuprazan offers several advantages over traditional PPIs, including a faster onset of action and a more consistent acid suppression. This can be particularly beneficial for patients who require rapid relief from acid-related symptoms. However, the choice between fexuprazan and other acid-reducing agents should be based on individual patient needs and clinical judgment.

Development and Approval

Fexuprazan was developed as part of ongoing efforts to improve the management of acid-related disorders. It has been approved for use in several countries and is undergoing further studies to expand its indications and optimize its use in clinical practice.

Related pages

• Proton pump inhibitor
• Gastroesophageal reflux disease
• Peptic ulcer disease